Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction : A double-blinded, randomized, and placebo-controlled trial. / Jensen, Jesper; Omar, Massar; Kistorp, Caroline; Poulsen, Mikael Kjær; Tuxen, Christian; Gustafsson, Ida; Køber, Lars; Gustafsson, Finn; Faber, Jens; Fosbøl, Emil L.; Bruun, Niels Eske; Brønd, Jan Christian; Forman, Julie Lyng; Videbæk, Lars; Møller, Jacob Eifer; Schou, Morten.

I: American Heart Journal, Bind 228, 2020, s. 47-56.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Jensen, J, Omar, M, Kistorp, C, Poulsen, MK, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Fosbøl, EL, Bruun, NE, Brønd, JC, Forman, JL, Videbæk, L, Møller, JE & Schou, M 2020, 'Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial', American Heart Journal, bind 228, s. 47-56. https://doi.org/10.1016/j.ahj.2020.07.011

APA

Jensen, J., Omar, M., Kistorp, C., Poulsen, M. K., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Faber, J., Fosbøl, E. L., Bruun, N. E., Brønd, J. C., Forman, J. L., Videbæk, L., Møller, J. E., & Schou, M. (2020). Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. American Heart Journal, 228, 47-56. https://doi.org/10.1016/j.ahj.2020.07.011

Vancouver

Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I o.a. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. American Heart Journal. 2020;228:47-56. https://doi.org/10.1016/j.ahj.2020.07.011

Author

Jensen, Jesper ; Omar, Massar ; Kistorp, Caroline ; Poulsen, Mikael Kjær ; Tuxen, Christian ; Gustafsson, Ida ; Køber, Lars ; Gustafsson, Finn ; Faber, Jens ; Fosbøl, Emil L. ; Bruun, Niels Eske ; Brønd, Jan Christian ; Forman, Julie Lyng ; Videbæk, Lars ; Møller, Jacob Eifer ; Schou, Morten. / Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction : A double-blinded, randomized, and placebo-controlled trial. I: American Heart Journal. 2020 ; Bind 228. s. 47-56.

Bibtex

@article{3b2199f963f8498793504d3b8336b185,
title = "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial",
abstract = "Aims: To investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin on N-terminal pro-b-type natriuretic peptide (NT-proBNP) in patients with heart failure (HF) and reduced ejection fraction (HFrEF). Methods and Results: Empire HF was an investigator-initiated, multi-center, double-blinded, placebo-controlled, randomized trial. Patients with mildly symptomatic HFrEF, mean (standard deviation (SD)) age 64 (11) years, 85% male, and mean left ventricular ejection fraction 29% (8), on recommended HF therapy were assigned to receive either empagliflozin 10 mg once daily or placebo for 12 weeks. The primary endpoint was the between-group difference in the change of NT-proBNP from baseline to 12 weeks. In total, 95 patients were assigned to empagliflozin and 95 to placebo. No significant difference in the change of NT-proBNP with empagliflozin versus placebo was observed [Empagliflozin: baseline, median (interquartile range (IQR)) 582 (304-1020) pg/mL, 12 weeks, 478 (281-961) pg/mL; Placebo: baseline, 605 (322-1070) pg/mL, 12 weeks, 520 (267-1075) pg/mL, adjusted ratio of change empagliflozin/placebo 0.98; 95% confidence interval (CI) 0.82-1.11, P = 0.7]. Further, no significant difference was observed in accelerometer-measured daily activity level [adjusted mean difference of change, empagliflozin versus placebo, -26.0 accelerometer counts; 95% CI -88.0 to 36.0, P = 0.4] or Kansas City Cardiomyopathy Questionnaire Overall Summary Score [adjusted mean difference of change, empagliflozin versus placebo 0.8; 95% CI -2.3 to 3.9, P = 0.6]. Conclusion: In low-risk patients with HFrEF with mild symptoms and on recommended HF therapy, empagliflozin did not change NT-proBNP after 12 weeks. Further, no change in daily activity level or health status was observed.",
author = "Jesper Jensen and Massar Omar and Caroline Kistorp and Poulsen, {Mikael Kj{\ae}r} and Christian Tuxen and Ida Gustafsson and Lars K{\o}ber and Finn Gustafsson and Jens Faber and Fosb{\o}l, {Emil L.} and Bruun, {Niels Eske} and Br{\o}nd, {Jan Christian} and Forman, {Julie Lyng} and Lars Videb{\ae}k and M{\o}ller, {Jacob Eifer} and Morten Schou",
year = "2020",
doi = "10.1016/j.ahj.2020.07.011",
language = "English",
volume = "228",
pages = "47--56",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

RIS

TY - JOUR

T1 - Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction

T2 - A double-blinded, randomized, and placebo-controlled trial

AU - Jensen, Jesper

AU - Omar, Massar

AU - Kistorp, Caroline

AU - Poulsen, Mikael Kjær

AU - Tuxen, Christian

AU - Gustafsson, Ida

AU - Køber, Lars

AU - Gustafsson, Finn

AU - Faber, Jens

AU - Fosbøl, Emil L.

AU - Bruun, Niels Eske

AU - Brønd, Jan Christian

AU - Forman, Julie Lyng

AU - Videbæk, Lars

AU - Møller, Jacob Eifer

AU - Schou, Morten

PY - 2020

Y1 - 2020

N2 - Aims: To investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin on N-terminal pro-b-type natriuretic peptide (NT-proBNP) in patients with heart failure (HF) and reduced ejection fraction (HFrEF). Methods and Results: Empire HF was an investigator-initiated, multi-center, double-blinded, placebo-controlled, randomized trial. Patients with mildly symptomatic HFrEF, mean (standard deviation (SD)) age 64 (11) years, 85% male, and mean left ventricular ejection fraction 29% (8), on recommended HF therapy were assigned to receive either empagliflozin 10 mg once daily or placebo for 12 weeks. The primary endpoint was the between-group difference in the change of NT-proBNP from baseline to 12 weeks. In total, 95 patients were assigned to empagliflozin and 95 to placebo. No significant difference in the change of NT-proBNP with empagliflozin versus placebo was observed [Empagliflozin: baseline, median (interquartile range (IQR)) 582 (304-1020) pg/mL, 12 weeks, 478 (281-961) pg/mL; Placebo: baseline, 605 (322-1070) pg/mL, 12 weeks, 520 (267-1075) pg/mL, adjusted ratio of change empagliflozin/placebo 0.98; 95% confidence interval (CI) 0.82-1.11, P = 0.7]. Further, no significant difference was observed in accelerometer-measured daily activity level [adjusted mean difference of change, empagliflozin versus placebo, -26.0 accelerometer counts; 95% CI -88.0 to 36.0, P = 0.4] or Kansas City Cardiomyopathy Questionnaire Overall Summary Score [adjusted mean difference of change, empagliflozin versus placebo 0.8; 95% CI -2.3 to 3.9, P = 0.6]. Conclusion: In low-risk patients with HFrEF with mild symptoms and on recommended HF therapy, empagliflozin did not change NT-proBNP after 12 weeks. Further, no change in daily activity level or health status was observed.

AB - Aims: To investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin on N-terminal pro-b-type natriuretic peptide (NT-proBNP) in patients with heart failure (HF) and reduced ejection fraction (HFrEF). Methods and Results: Empire HF was an investigator-initiated, multi-center, double-blinded, placebo-controlled, randomized trial. Patients with mildly symptomatic HFrEF, mean (standard deviation (SD)) age 64 (11) years, 85% male, and mean left ventricular ejection fraction 29% (8), on recommended HF therapy were assigned to receive either empagliflozin 10 mg once daily or placebo for 12 weeks. The primary endpoint was the between-group difference in the change of NT-proBNP from baseline to 12 weeks. In total, 95 patients were assigned to empagliflozin and 95 to placebo. No significant difference in the change of NT-proBNP with empagliflozin versus placebo was observed [Empagliflozin: baseline, median (interquartile range (IQR)) 582 (304-1020) pg/mL, 12 weeks, 478 (281-961) pg/mL; Placebo: baseline, 605 (322-1070) pg/mL, 12 weeks, 520 (267-1075) pg/mL, adjusted ratio of change empagliflozin/placebo 0.98; 95% confidence interval (CI) 0.82-1.11, P = 0.7]. Further, no significant difference was observed in accelerometer-measured daily activity level [adjusted mean difference of change, empagliflozin versus placebo, -26.0 accelerometer counts; 95% CI -88.0 to 36.0, P = 0.4] or Kansas City Cardiomyopathy Questionnaire Overall Summary Score [adjusted mean difference of change, empagliflozin versus placebo 0.8; 95% CI -2.3 to 3.9, P = 0.6]. Conclusion: In low-risk patients with HFrEF with mild symptoms and on recommended HF therapy, empagliflozin did not change NT-proBNP after 12 weeks. Further, no change in daily activity level or health status was observed.

U2 - 10.1016/j.ahj.2020.07.011

DO - 10.1016/j.ahj.2020.07.011

M3 - Journal article

C2 - 32798787

AN - SCOPUS:85089349743

VL - 228

SP - 47

EP - 56

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -

ID: 247949000